Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70845 ↗At a glance
Journal article in Diabetes, Obesity and Metabolism, 2026. Written by Viveca Ritsinger and 6 co-authors. Institution: Division of Cardiology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden. Major MEDLINE topics: Obesity, Cardiovascular Diseases. 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: Novo Nordisk Scandinavia AB, Uppsala Universitet, Swedish Heart-Lung Foundation.
Abstract (original language)
Aims
To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in Sweden) database to identify adults with a recorded BMI ≥ 30 kg/m 2 between January 2013 and June 2023. Individuals were stratified by obesity class. Baseline demographics, comorbidities, medications and laboratory values were described. Outcomes included recorded obesity prevalence, obesity diagnosis (ICD‐10: E66), healthcare setting at first BMI ≥ 30 kg/m 2 , cardiometabolic comorbidity profiles, treatment patterns and long‐term cardiovascular outcomes. Cardiovascular outcomes were compared with a matched general population.
Results
In 2022, recorded obesity prevalence was 13.6%. Amongst 328 094 individuals with obesity (mean age 53.5 years; 55.0% women), 67.6% had at least one cardiometabolic comorbidity. At the first observed BMI ≥ 30 kg/m 2 (index), 28.8% had a recorded obesity diagnosis, increasing to 48.0% 5 years later. Index BMI was most often recorded in primary care (39.7%). Within 5 years after index, 7.8% had received obesity‐management medication and 4.2% had undergone bariatric surgery. Compared with matched population representatives, the obesity cohort had higher cumulative incidence across all cardiovascular outcomes, with the largest relative difference for heart failure hospitalisation (HR 2.34, 95% CI 2.29–2.40).
Conclusions
Obesity remains underdiagnosed and undertreated in Swedish healthcare, despite a high burden of cardiometabolic comorbidities and substantially higher long‐term cardiovascular risk compared with the general population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Cardiology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
- Department of Research and Development, Region Kronoberg, Växjö, Sweden.
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- Novo Nordisk Scandinavia AB, Malmö, Sweden.
- Sence Research AB, Uppsala, Sweden.
- Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden.
ORCID profiles: Viveca Ritsinger, Anna Norhammar
Funding
- Novo Nordisk Scandinavia AB
- Uppsala Universitet
- Swedish Heart-Lung Foundation
- ALF Medicine, Region Stockholm
- Department of Research and Development, Region Kronoberg
Cite
APA
Ritsinger, V., Sundbom, M., Dereke, J., Ericsson, Å., Cars, T., Svensson, M. K., & Norhammar, A. (2026). Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70845
Vancouver
Ritsinger V, Sundbom M, Dereke J, Ericsson Å, Cars T, Svensson MK, et al. Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70845
BibTeX
@article{Ritsinger2026,
author = {Ritsinger, Viveca and Sundbom, Magnus and Dereke, Jonatan and Ericsson, Åsa and Cars, Thomas and Svensson, Maria K and Norhammar, Anna},
title = {Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70845}
}
EUVIMED